Novavax Inc. Files 2024 Annual Report

Ticker: NVAX · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1000694

Novavax Inc 10-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type10-K
Filed DateFeb 27, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, biotechnology, vaccines

TL;DR

Novavax filed its 2024 10-K. Full financials and biz details inside.

AI Summary

Novavax Inc. reported its 2024 fiscal year results, ending December 31, 2024. The company's filing details its financial performance and business operations. Key financial figures and operational highlights for the year are presented within this 10-K report.

Why It Matters

This filing provides investors and the public with a comprehensive overview of Novavax's financial health and strategic direction for the past fiscal year. It is crucial for understanding the company's performance and future prospects.

Risk Assessment

Risk Level: medium — The company operates in the highly competitive and regulated biotechnology sector, facing risks related to product development, market adoption, and financial performance.

Key Numbers

  • 2024 — Fiscal Year (Reporting period for the 10-K filing.)
  • 1231 — Fiscal Year End (Indicates the end date of the fiscal year reported.)
  • 2025-02-27 — Filing Date (Date the 10-K was officially submitted to the SEC.)

Key Players & Entities

  • NOVAVAX INC (company) — Filer
  • 2024-12-31 (date) — Fiscal Year End
  • 2025-02-27 (date) — Filing Date
  • 700 QUINCE ORCHARD ROAD (address) — Business Address
  • GAITHERSBURG (city) — Business Address City
  • MD (state) — Business Address State
  • 20878 (zip_code) — Business Address Zip
  • 240-268-2000 (phone_number) — Business Phone

FAQ

What is Novavax Inc.'s primary business?

Novavax Inc. is primarily involved in the development and commercialization of vaccines for infectious diseases, as indicated by its SIC code for Biological Products.

When did Novavax Inc. file its 2024 10-K report?

Novavax Inc. filed its 2024 10-K report on February 27, 2025.

What is Novavax Inc.'s fiscal year end?

Novavax Inc.'s fiscal year ends on December 31st.

Where is Novavax Inc. headquartered?

Novavax Inc.'s business and mailing address is 700 Quince Orchard Road, Gaithersburg, MD 20878.

What is the SEC file number for Novavax Inc.'s 10-K filings?

The SEC file number for Novavax Inc. is 000-26770.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding NOVAVAX INC (NVAX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.